Pharmaceuticals News and Research

RSS

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that data from its Hsp90 chaperone and Hedgehog pathway inhibitor programs will be presented during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Ill. from June 4 through June 8, 2010.

21 May 2010

VIA-2291 can reduce inflammation in patients with atherosclerosis: Study

The results of a major clinical study carried out at the Montreal Heart Institute by Dr. Jean-Claude Tardif are now available in the journal Circulation Cardiovascular Imaging. Dr. Tardif is a cardiologist and director of the MHI Research Centre, as well as a professor in the faculty of medicine and holder of the atherosclerosis research chair at the Universit- de Montr-al.

21 May 2010

Salix announces additional intellectual property protection for rifaximin in treatment of IBS

Salix Pharmaceuticals, Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,718,608. This patent provides protection until August 2019 for rifaximin, which Salix markets in the United States under the trade names XIFAXAN® (200mg) and XIFAXAN550™ (550mg).

21 May 2010

JCVI researchers construct first self-replicating, synthetic bacterial cell

Researchers at the J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, published results today describing the successful construction of the first self-replicating, synthetic bacterial cell. The team synthesized the 1.08 million base pair chromosome of a modified Mycoplasma mycoides genome.

21 May 2010

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Toxcure, LLC, an emerging specialty biopharmaceutical company, today announced the grant of U.S. Patent No. 7,709,440, which provides Toxcure with intellectual property protection for a method of treating various tumors with neurotoxins.

21 May 2010

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer for one of the company's investigational compounds, BIBW 2992. These data will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology annual meeting in Chicago.

21 May 2010

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Onyx Pharmaceuticals, Inc. today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL.

21 May 2010

Abbott to acquire Piramal's Healthcare Solutions business

Abbott announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion, plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market.

21 May 2010

COTI reports positive results from first phase of HIV integrase inhibitor discovery program

Critical Outcome Technologies Inc. today announced positive results from the first phase of its HIV integrase inhibitor discovery program. These results provide novel intellectual property to the Company and further validation of the CHEMSAS® drug discovery technology.

21 May 2010

EpiCept launches Ceplene in Germany

EpiCept Corporation today announced the commercial launch of Ceplene (R) (histamine dihydrochloride) in Germany. The launch is being conducted by Meda AB, as part of an exclusive commercialization agreement for Ceplene signed by the two companies in January 2010.

21 May 2010

WHA addresses counterfeit medicines

Discussions about combatting counterfeit medicines continued at the 63rd World Health Assembly (WHA) in Geneva on Wednesday, Agence France-Press reports

21 May 2010

GSK, EMBL-EBI, NLM and CDD collaborate to apply principles of open source to drug discovery for malaria

GlaxoSmithKline (GSK) had teamed up with leading public-domain data providers European Bioinformatics Institute (EMBL-EBI), the U.S. National Library of Medicine (NLM) and the U.S.-based informatics service provider Collaborative Drug Discovery (CDD) to make freely available key scientific information on more than 13,500 compounds that could ultimately lead to new treatments for malaria.

20 May 2010

Invida Group completes joint venture agreement with MUGI

Invida Group, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has completed a joint venture agreement with the Indonesian pharmaceutical manufacturer MUGI.

20 May 2010

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.

20 May 2010

BioLife Solutions first-quarter revenue up 36% to $513,000

BioLife Solutions, Inc., announced today that Chairman and Chief Executive Officer Mike Rice issued the following letter to shareholders providing a general corporate update.

20 May 2010

NeuroTherapeutics Pharma closes $43 million Series B financing round

NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co-led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round.

20 May 2010

Patterson's consolidated sales for fourth-quarter fiscal 2010 up 4%

Patterson Companies, Inc. today reported consolidated sales of $812,762,000 for the fourth quarter of fiscal 2010 ended April 24, an increase of 4% from $779,884,000 in the year-earlier quarter. Internal growth accounted for 1% of the fourth quarter sales increase, with acquisitions and foreign currency adjustments accounting for the balance.

20 May 2010

New study uses NMR in drug design

A new study by a team of researchers led by Jeffrey Peng, assistant professor of chemistry and biochemistry at the University of Notre Dame, is using Nuclear Magnetic Resonance, to move drug design into groundbreaking consideration of the dynamic flexibility of drugs and their targets.

20 May 2010

Pharmaceuticals News and Research

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Genentech to present new data for targeted cancer medicines at 46th ASCO

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

VIA-2291 can reduce inflammation in patients with atherosclerosis: Study

Salix announces additional intellectual property protection for rifaximin in treatment of IBS

JCVI researchers construct first self-replicating, synthetic bacterial cell

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Abbott to acquire Piramal's Healthcare Solutions business

COTI reports positive results from first phase of HIV integrase inhibitor discovery program

EpiCept launches Ceplene in Germany

WHA addresses counterfeit medicines

GSK, EMBL-EBI, NLM and CDD collaborate to apply principles of open source to drug discovery for malaria

Invida Group completes joint venture agreement with MUGI

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

BioLife Solutions first-quarter revenue up 36% to $513,000

NeuroTherapeutics Pharma closes $43 million Series B financing round

Patterson's consolidated sales for fourth-quarter fiscal 2010 up 4%

New study uses NMR in drug design

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence